Metastatic Prostate Cancer – Bone Metastases Might Be Controled With Xofigo For Two or More Years

/, Hormone Therapy/Metastatic Prostate Cancer – Bone Metastases Might Be Controled With Xofigo For Two or More Years

Metastatic Prostate Cancer suffers have good news.  Xofigo, also known as Radium-223 (Ra-223), is a treatment for patients with castration-resistant prostate cancer (CRPC) and symptomatic (you can feel them) bone metastases (mets).  Early results of an international, open-label, phase 1/2 study (NCT01934790) showed that re-treating pts with Ra-223 was well tolerated with favorable effects on disease progression.  You can also be on abiraterone, enzalutamide at the same time. There were no serious drug-related problems for the 44 patients in this study.  This study should give you and your oncologist more confidence that you can have two rounds of Xofigo for castrate resistant and bone metastases treatment during a two year period of time.     The study will continue for another five years.  

By |2018-02-06T11:09:18+00:00February 5th, 2018|Advanced Prostate Cancer, Hormone Therapy|0 Comments

About the Author:

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

Leave A Comment